The Europe fill finish pharmaceutical contract manufacturing market size is expected to reach USD 9.54 billion by 2030, expanding at a CAGR of 8.5% from 2025 to 2030. The market is driven by factors such as the increasing demand for sterile injectable drugs, the rising prevalence of chronic diseases, and the growing focus on cost containment and efficiency by pharmaceutical companies. Additionally, advancements in technology and the increasing use of contract manufacturing by pharmaceutical companies are expected to drive market growth.
The Europe fill finish pharmaceutical contract manufacturing market is also characterized by a number of trends, such as the growing importance of regulatory compliance, the increasing use of single-use technology, and the rising adoption of advanced analytical and quality control systems. Additionally, there is a growing trend towards the use of contract manufacturing by small and mid-sized pharmaceutical companies, as well as by virtual biotech companies.
Germany dominated the market in 2024 owing to a strong base of biotechnology and pharmaceutical companies in the region. These companies are involved in drug discovery activities, which, in turn, led to the growth of the market in the region. The COVID-19 pandemic has had a significant impact, and one of the major impacts of the pandemic on the fill-finish contract manufacturing market in Europe has been an increased demand for COVID-19 vaccines and therapies. This has aided in increasing the demand for CMOs in the market since the fill-finish process requires advanced technology; thus, to reduce the cost, many Pharma and Biotech companies are more focused on outsourcing the fill-finish process, thereby boosting the overall market growth.
This product will be delivered within 1-3 business days.
The Europe fill finish pharmaceutical contract manufacturing market is also characterized by a number of trends, such as the growing importance of regulatory compliance, the increasing use of single-use technology, and the rising adoption of advanced analytical and quality control systems. Additionally, there is a growing trend towards the use of contract manufacturing by small and mid-sized pharmaceutical companies, as well as by virtual biotech companies.
Germany dominated the market in 2024 owing to a strong base of biotechnology and pharmaceutical companies in the region. These companies are involved in drug discovery activities, which, in turn, led to the growth of the market in the region. The COVID-19 pandemic has had a significant impact, and one of the major impacts of the pandemic on the fill-finish contract manufacturing market in Europe has been an increased demand for COVID-19 vaccines and therapies. This has aided in increasing the demand for CMOs in the market since the fill-finish process requires advanced technology; thus, to reduce the cost, many Pharma and Biotech companies are more focused on outsourcing the fill-finish process, thereby boosting the overall market growth.
Europe Fill Finish Pharmaceutical Contract Manufacturing Market Report Highlights
- On the basis of product type, Vials dominated the market and accounted for a share of 53.4% in 2024 and Prefilled syringes are expected to grow at the fastest CAGR of 9.6% over the forecast period.
- Based on the Molecule type, the small molecule segment dominated the market in 2022 with the largest share of 67.3% in 2024 and is anticipated to show lucrative growth over the forecast period.
- Based on the End-use segment, the biopharmaceutical segment dominated the market and accounted for the largest revenue share of 35.9% in 2024. The increasing demand for biologics and biosimilars is driving the growth of the biopharmaceutical end-use segment. Due to the market for biologics and biosimilars experiencing rapid expansion, biopharmaceutical companies are the main consumers of fill-finish contract manufacturing services.
- The UK fill-finish pharmaceutical contract manufacturing market held the largest market share of 20.3% in 2024 in the Europe market and the fill-finish pharmaceutical contract manufacturing market in Germany is expected to grow at the fastest CAGR of 11.0% over the forecast period.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Europe Fill-finish Pharmaceutical Contract Manufacturing Market Variables, Trends, & Scope
Chapter 4. Europe Fill-finish Pharmaceutical Contract Manufacturing Market: Product Business Analysis
Chapter 5. Europe Fill-finish Pharmaceutical Contract Manufacturing Market: Molecule Business Analysis
Chapter 6. Europe Fill-finish Pharmaceutical Contract Manufacturing Market: End Use Business Analysis
Chapter 7. Europe Fill-finish Pharmaceutical Contract Manufacturing Market: Country Estimates & Trend Analysis by Product, Molecule, and End Use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Sartorius AG
- Boehringer Ingelheim International GmbH
- Catalent, Inc (acquired by Novo Holdings A/S)
- Societal CDMO (Recro Pharma, Inc)
- Baxter
- Eurofins Scientific
- Symbiosis Pharmaceutical Services Ltd
- MabPlex International Co. Ltd.
- Recipharm AB
- Fresenius Kabi, USA LLC
- Lonza
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | November 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 5.81 Billion |
| Forecasted Market Value ( USD | $ 9.54 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 12 |
